The UCCCC senior leadership is committed to funding protocols that have the highest potential for leading to larger scale clinical trials with the possibility of significant clinical impact and/or future external peer-reviewed funding. These studies are innovative, feasibility, or proof-of-principle studies that are deemed to be of highest priority to the Cancer Center. In the last budget period, priorities included the promotion of interdisciplinary, translational, and population research, as well as diversification of the types of trials funded by this mechanism. It is anticipated that Protocol-Specific Research (PSR) funds will support approximately 2 trials per year and will be used to fund the effort of nurses and data managers. The UCCCC issues an RFA, with specified deadlines, which is posted on the UCCCC website, distributed to Program Leaders and members of the Cancer Advisory Committee, and sent to all UCCCC members via email. The RFA outlines the application requirements, which include submission of the full study protocol, together with a one-page description of the importance and innovativeness of the study and rationale for funding, as well as a budget and budget justification. Per NCI guidelines, all studies must be investigator initiated, not otherwise funded, IRB-approved, and the budgets restricted to nursing and data management support. PSR proposals are reviewed by a committee comprised of the Director, Co-Deputy Director for Clinical Sciences, and the Associate Directors for Clinical, Basic, Translational, and Population Research. The review process takes into consideration scientific merit, innovativeness, and the likelihood that the project will lead to future large scale clinical trials or extramural funding. Funded projects are monitored on a regular basis, and accrual reports are required quarterly. If a protocol is accruing poorly, and/or it is no longer feasible to conduct the trial, the Director, in consultation with the Associate Directors, will suspend funding. Over the past 5 years, our procedures for soliciting and awarding PSR have been modified slightly. Rather than set specific submission deadlines, we have allowed for a more flexible (rolling) submission schedule to accommodate new studies opening throughout the year. In addition, protocols are first submitted to the Clinical Trials Review Committee (CTRC), and CTRC comments are provided to the reviewers. These same procedures will be employed in the next grant cycle to fund approximately two early-phase studies per year.

Public Health Relevance

The UCCCC has an extensive and strong clinical trials program. Our goal is to provide the best and most personalized treatments available as well as to develop new treatment approaches. Protocol-specific research funds provide a vehicle for supporting early-phase testing of new drugs, modalities or devices and as well as new applications of therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014599-39
Application #
8744844
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
39
Fiscal Year
2014
Total Cost
$52,687
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Feng, Christine H; Gerry, Emily; Chmura, Steven J et al. (2015) An image-guided study of setup reproducibility of postmastectomy breast cancer patients treated with inverse-planned intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys 91:58-64
Ming, Mei; Zhao, Baozhong; Shea, Christopher R et al. (2015) Loss of sirtuin 1 (SIRT1) disrupts skin barrier integrity and sensitizes mice to epicutaneous allergen challenge. J Allergy Clin Immunol 135:936-45.e4
Ming, Mei; Zhao, Baozhong; Qiang, Lei et al. (2015) Effect of immunosuppressants tacrolimus and mycophenolate mofetil on the keratinocyte UVB response. Photochem Photobiol 91:242-7
Shah, Palak; He, Yu-Ying (2015) Molecular regulation of UV-induced DNA repair. Photochem Photobiol 91:254-64
Ming, Mei; Han, Weinong; Zhao, Baozhong et al. (2014) SIRT6 promotes COX-2 expression and acts as an oncogene in skin cancer. Cancer Res 74:5925-33
Ramírez, Jacqueline; Kim, Tae Won; Liu, Wanqing et al. (2014) A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469. Pharmacogenet Genomics 24:129-32
Rudra, Sonali; Al-Hallaq, Hania A; Feng, Christine et al. (2014) Effect of RTOG breast/chest wall guidelines on dose-volume histogram parameters. J Appl Clin Med Phys 15:4547
Weng, Liming; Ziliak, Dana; Lacroix, Bonnie et al. (2014) Integrative "omic" analysis for tamoxifen sensitivity through cell based models. PLoS One 9:e93420
Stumpf, Melanie; Zhou, Xuyu; Chikuma, Shunsuke et al. (2014) Tyrosine 201 of the cytoplasmic tail of CTLA-4 critically affects T regulatory cell suppressive function. Eur J Immunol 44:1737-46
Geeleher, Paul; Cox, Nancy J; Huang, R Stephanie (2014) Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines. Genome Biol 15:R47

Showing the most recent 10 out of 354 publications